Physician profile
Linh Chieu
NPI 1255954673
$2,432.56
in general payments reported to CMS, 2019-2025
18 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $387 · 2022: $874 · 2023: $169 · 2024: $597 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,172.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $583.43 | 2021-2025 | Misight Contact Lens, Myday Contact Lens, Paragon Crt |
| Abbvie INC. | $395.55 | 2022-2025 | Lumigan, Durysta |
| Sun Pharmaceutical Industries INC. | $250.75 | 2024-2025 | |
| Allergan, INC. | $207.22 | 2022 | |
| Bausch & Lomb Americas INC. | $189.55 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Harrow Eye, LLC | $175.80 | 2024-2025 | Vevye |
| Johnson & Johnson Vision Care, INC. | $139.28 | 2022 | |
| Oyster Point Pharma, INC. | $126.69 | 2022-2024 | Tyrvaya |
| Carl Zeiss Meditec, INC. | $70.91 | 2021 | |
| Kala Pharmaceuticals, INC. | $55.52 | 2021-2022 | |
| Rxsight INC | $53.93 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Tarsus Pharmaceuticals, INC. | $52.48 | 2024 | Xdemvy |
| Alcon Vision LLC | $50.26 | 2022 | |
| Thea Pharma INC. | $18.71 | 2025 | Iyuzeh |
| Dompe US, INC. | $18.44 | 2025 | Oxervate |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.75 | 2022 | |
| Ocular Therapeutix, INC. | $14.54 | 2024 | Dextenza |
| Aerie Pharmaceuticals, INC. | $13.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linh Chieu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.